Cellebrite DI Ltd. $CLBT Shares Acquired by Greenhaven Road Investment Management L.P.

Greenhaven Road Investment Management L.P. lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 8.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,653,047 shares of the company’s stock after buying an additional 135,000 shares during the quarter. Cellebrite DI accounts for approximately 4.5% of Greenhaven Road Investment Management L.P.’s holdings, making the stock its 3rd largest holding. Greenhaven Road Investment Management L.P. owned about 0.69% of Cellebrite DI worth $30,631,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CLBT. Financial Management Professionals Inc. acquired a new stake in Cellebrite DI in the third quarter valued at approximately $28,000. CWM LLC lifted its position in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after purchasing an additional 720 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after purchasing an additional 1,998 shares during the period. Toth Financial Advisory Corp purchased a new position in shares of Cellebrite DI in the third quarter valued at $38,000. Finally, Advisory Services Network LLC acquired a new stake in Cellebrite DI during the 3rd quarter valued at $40,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $14.58 on Thursday. Cellebrite DI Ltd. has a 1 year low of $11.76 and a 1 year high of $20.86. The firm’s 50-day simple moving average is $15.04 and its 200-day simple moving average is $16.86. The firm has a market cap of $3.64 billion, a PE ratio of 47.03, a price-to-earnings-growth ratio of 2.25 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, hitting analysts’ consensus estimates of $0.14. The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the firm earned $0.10 earnings per share. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CLBT shares. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cellebrite DI has an average rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.